2022
Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?
Zhao Y, Haroun R, Sahu S, Schernthaner R, Smolka S, Lin M, Hong K, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers 2022, 14: 3615. PMID: 35892874, PMCID: PMC9329887, DOI: 10.3390/cancers14153615.Peer-Reviewed Original ResearchOverall survivalSecond TACEHepatocellular carcinoma patientsFirst TACECarcinoma patientsTumor responseInitial transarterial chemoembolizationMedian overall survivalTransarterial chemoembolization sessionsKaplan-Meier methodLonger overall survivalLog-rank testChemoembolization sessionsConsecutive patientsTransarterial chemoembolizationSurvival outcomesHCC patientsTreatment responseTumor enhancementPatientsSurvival analysisTACEEuropean AssociationRespondersSignificant differences
2020
Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment
Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. Clinical Cancer Research 2020, 26: 428-438. PMID: 31582517, PMCID: PMC7244230, DOI: 10.1158/1078-0432.ccr-19-1702.Peer-Reviewed Original ResearchConceptsMR spectroscopic imagingLocoregional therapyLiver cancer microenvironmentConventional transarterial chemoembolizationNew Zealand white rabbitsTumor pHMost liver tumorsZealand white rabbitsMolecular imaging paradigmsPositive therapeutic outcomesTumor residualsTransarterial chemoembolizationTumor devascularizationHistopathologic markersViable tumorSurrogate biomarkerLiver tumorsLiver cancerTumor enhancementLiver parenchymaMetabolic markersMultiparametric MRITherapeutic outcomesHIF-1αVX2 tumors
2015
Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement
Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. European Radiology 2015, 26: 103-113. PMID: 25994198, PMCID: PMC4654989, DOI: 10.1007/s00330-015-3812-2.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationHCC patientsIpsilateral placementTumor enhancementHepatocellular carcinoma patientsROI placementContrast-enhanced MR imagingRadiologic-pathologic analysisArterial chemoembolizationCarcinoma patientsPathological correlationIntra-class correlationPatientsMR imagingClinical methodsMedian differencePathologyInterest placementHistopathology
2014
Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization
Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic LJ, Tacher V, Kamel IR, Geschwind JF. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology 2014, 7: 447-455. PMID: 24953419, PMCID: PMC4202794, DOI: 10.1016/j.tranon.2014.05.004.Peer-Reviewed Original ResearchFirst transarterial chemoembolizationEarly tumor responseTransarterial chemoembolizationWorld Health OrganizationOverall survivalTumor responseTarget lesionsTumor volumeTumor enhancementUveal melanomaContrast-enhanced magnetic resonance imagingNon-target lesionsUveal melanoma metastaticMedian overall survivalResponse Evaluation CriteriaKaplan-Meier methodLog-rank testMetastatic uveal melanomaMagnetic resonance imagingMelanoma metastaticSurrogate biomarkerSolid tumorsResonance imagingResponse criteriaLesions
2013
Can C-Arm Cone-Beam CT Detect a Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and Carcinoid Liver Metastasis?
Pellerin O, Lin M, Bhagat N, Shao W, Geschwind J. Can C-Arm Cone-Beam CT Detect a Micro-Embolic Effect After TheraSphere Radioembolization of Neuroendocrine and Carcinoid Liver Metastasis? Cancer Biotherapy & Radiopharmaceuticals 2013, 28: 459-465. PMID: 23484809, PMCID: PMC3715773, DOI: 10.1089/cbr.2012.1390.Peer-Reviewed Original ResearchConceptsTumor enhancementHounsfield unitsArterial phaseCapillary levelCarcinoid liver metastasesYttrium-90 microspheresHigh-dose radiationEarly arterial phaseContrast medium injectionC-arm cone-beam CTTheraSphere radioembolizationLiver metastasesNeuroendocrine tumorsHepatic tumorsDelayed phasesRadioembolizationTumor densityMedium injectionTumor attenuationTumor vesselsTumorsTheraSphereEmbolic effectCone-beam CTSignificant decrease
2012
Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization
Lin M, Pellerin O, Bhagat N, Rao P, Loffroy R, Ardon R, Mory B, Reyes D, Geschwind J. Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization. Journal Of Vascular And Interventional Radiology 2012, 23: 1629-1637. PMID: 23177109, PMCID: PMC3579576, DOI: 10.1016/j.jvir.2012.08.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansImaging, Three-DimensionalLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPattern Recognition, AutomatedReproducibility of ResultsSensitivity and SpecificitySoftwareSoftware ValidationTreatment OutcomeTumor BurdenConceptsTranscatheter arterial chemoembolizationArterial chemoembolizationHepatocellular carcinomaDrug-eluting bead transcatheter arterial chemoembolizationSingle-institution prospective studyResponse Evaluation CriteriaContrast-enhanced magnetic resonanceHepatic tumor volumeSolid tumor measurementsThree-dimensional volumetric assessmentMagnetic resonanceIntraarterial therapyProspective studyTumor responseClinical correlationTumor measurementsTumor volumeTumor enhancementInterventional radiologistsPatientsVolumetric assessmentChemoembolizationEuropean AssociationVolume assessmentVoxel basisIntraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma?
Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF. Intraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma? Radiology 2012, 266: 636-648. PMID: 23143027, PMCID: PMC3558876, DOI: 10.1148/radiol.12112316.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArea Under CurveCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyDoxorubicinFemaleHumansLeast-Squares AnalysisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of TestsProspective StudiesRadiation DosageROC CurveSwineTreatment OutcomeConceptsDual-phase cone-beam CTTranscatheter arterial chemoembolizationPartial tumor responseDrug-eluting beadsTumor responseTumor enhancementCone-beam CT scansHepatocellular carcinomaLogistic regression modelsCone-beam CTVenous phaseCT scanMR findingsMultivariate logistic regression modelMR imagingHCC tumor responseRadiation doseDoxorubicin-eluting beadsMagnetic resonance imagingInstitutional review boardArterial chemoembolizationLiver (EASL) guidelinesRegression modelsProspective studyHCC lesions